XNYS · Medical Instruments & Supplies
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$212.61-1.23%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
52/100
Moderate
Score components
TickerWhale View
Becton Dickinson & Company scores 52 out of 100 overall, which we rate moderate. Technical is its strongest area and Risk its weakest.
What helps
- Technical
- Sentiment Signal
What to watch
- Quality & growth
- Valuation
- Risk
Quality & growth
30%34Weak
- Revenue growth 5.2%
- EPS growth -39.5%
Valuation
25%44Weak
- P/E 62.2
- EV/Sales 3.6
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
#225 by market cap in our coverage · ~72,000 employees · Listed 1963-09-25 · www.bd.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#89 / 139sector rank by TickerWhale Score
TickerWhale Score 52 vs sector average 54.6 (-2.6)
Revenue growth (industry)Top 79%
Gross margin (industry)Top 67%
Return on equity (industry)Top 53%
P/E (industry)Pricier than 75%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
94/100Strong vs universe
Ranks 94th of 100 covered names on our technical composite — the composite itself scores 83/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
5 buy · 3 sell · 0 neutral of 8 votes
TickerWhale rates BDX's technical setup strong — 94th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+25.2%
- vs 50-day+12.4%
Momentum
Weak
- RSI (14)71 · sell
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength55· trending
- MACD (12,26,9)buy(histogram 1.473)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 3 sell · 0 neutral.
Result — 5 buy vs 3 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)62.2
- P/S (TTM)2.8
- P/B2.4
- EV/EBITDA—
- EV/Sales3.6
- PEG—
Profitability & returns
- Gross margin46.4%
- Net margin4.5%
- ROE3.9%
- Debt/Equity0.69
Growth
- Revenue growth (YoY)5.2%
- EPS growth (YoY)-39.5%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $58.5B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Sep '25 | Sep '24 | Sep '23 |
|---|---|---|---|
| Revenue | $21.8B | $20.2B | $19.4B |
| Gross profit | $9.9B | $9.1B | $8.2B |
| Operating income | $2.6B | $2.4B | $2.1B |
| Net income | $1.7B | $1.7B | $1.5B |
| EPS (diluted) | $5.82 | $5.86 | $4.94 |
| Free cash flow | $2.7B | $3.1B | $2.1B |
| Cash | $777M | $1.9B | $1.5B |
| Total debt | $19.2B | $20.1B | $15.9B |
| Equity | $25.4B | $25.9B | $25.8B |
| Net debt | $18.4B | $18.3B | $14.4B |
| Debt / equity | 0.76 | 0.78 | 0.62 |
| Liabilities / assets | 0.54 | 0.55 | 0.51 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BDXCurrentBecton Dickinson & Company | 52 | 83 | 62.2 | — | 2.4 | 3.6 | $212.61 | -1.23% | +5.2% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.